title: Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.
abstract: Enzyme pro-drug suicide gene therapy has been hindered by inefficient viral delivery and gene transduction. To further explore the potential of this approach, we have developed AdIU1, a prostate-restricted replicative adenovirus (PRRA) armed with the herpes simplex virus thymidine kinase (HSV-TK). In our previous Ad-OC-TK/ACV phase I clinical trial, we demonstrated safety and proof of principle with a tissue-specific promoter-based TK/pro-drug therapy using a replication-defective adenovirus for the treatment of prostate cancer metastases. In this study, we aimed to inhibit the growth of androgen-independent (AI), PSA/PSMA-positive prostate cancer cells by AdIU1. In vitro the viability of an AI- PSA/PSMA-expressing prostate cancer cell line, CWR22rv, was significantly inhibited by treatment with AdIU1 plus GCV (10 microg ml(-1)), compared with AdIU1 treatment alone and also cytotoxicity was observed following treatment with AdIU1 plus GCV only in PSA/PSMA-positive CWR22rv and C4-2 cells, but not in the PSA/PSMA-negative cell line, DU-145. In vivo assessment of AdIU1 plus GCV treatment revealed a stronger therapeutic effect against CWR22rv tumors in nude mice than treatment with AdIU1 alone, AdE4PSESE1a alone or in combination with GCV. Our results demonstrate the therapeutic potential of specific-oncolysis and suicide gene therapy for AI-PSA/PSMA-positive prostate cancer gene therapy.
authors.affiliation: Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
authors.forename: M
authors.initials: M
authors.lastname: Ahn
authors.forename: S-J
authors.initials: SJ
authors.lastname: Lee
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: J A
authors.initials: JA
authors.lastname: Jiménez
authors.forename: Y-P
authors.initials: YP
authors.lastname: Zhang
authors.forename: K-H
authors.initials: KH
authors.lastname: Bae
authors.forename: Y
authors.initials: Y
authors.lastname: Mohammadi
authors.forename: C
authors.initials: C
authors.lastname: Kao
authors.forename: T A
authors.initials: TA
authors.lastname: Gardner
mesh_terms: D000256:Adenoviridae; D000818:Animals; D045744:Cell Line, Tumor; D041722:Genes, Transgenic, Suicide; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000096:biosynthesis / Q000235:genetics; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000235:genetics / Q000628:therapy*; D018139:Simplexvirus / Q000201:enzymology / Q000235:genetics; D013937:Thymidine Kinase / Q000096:biosynthesis / Q000235:genetics; D014764:Viral Proteins / Q000096:biosynthesis / Q000235:genetics
chemical_list: D014764:Viral Proteins; D013937:Thymidine Kinase; D017430:Prostate-Specific Antigen
references.citation: Clin Chem. 2002 Aug;48(8):1198-205
references.pmid: 12142373
references.citation: Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):873-85
references.pmid: 12377341
references.citation: Gene Ther. 2003 Jul;10(13):1129-34
references.pmid: 12808443
references.citation: BJU Int. 2000 Apr;85(6):759-66
references.pmid: 10759680
references.citation: J Virol. 2002 Dec;76(24):12483-90
references.pmid: 12438574
references.citation: Cancer Res. 2000 Jan 15;60(2):334-41
references.pmid: 10667585
references.citation: Gene Ther. 2001 Sep;8(18):1416-26
references.pmid: 11571582
references.citation: Gene Ther. 2001 Jun;8(12):946-53
references.pmid: 11426335
references.citation: Mol Ther. 2006 Jul;14(1):107-17
references.pmid: 16690359
references.citation: Curr Gene Ther. 2006 Dec;6(6):647-70
references.pmid: 17168697
references.citation: Mol Ther. 2002 Sep;6(3):415-21
references.pmid: 12231179
references.citation: Cancer Res. 1999 Apr 1;59(7):1498-504
references.pmid: 10197620
references.citation: Cancer Res. 2003 Nov 1;63(21):7497-506
references.pmid: 14612551
references.citation: Hum Gene Ther. 1999 Jul 1;10(10):1721-33
references.pmid: 10428217
references.citation: Bioorg Med Chem Lett. 2003 Nov 17;13(22):3933-8
references.pmid: 14592478
references.citation: J Mol Biol. 2003 Jul 18;330(4):749-60
references.pmid: 12850144
references.citation: Cancer Res. 2001 Oct 15;61(20):7464-72
references.pmid: 11606381
references.citation: Hum Gene Ther. 2000 Jan 1;11(1):67-76
references.pmid: 10646640
references.citation: Cancer Gene Ther. 2001 Dec;8(12):927-35
references.pmid: 11781655
references.citation: Curr Gene Ther. 2005 Aug;5(4):411-27
references.pmid: 16101515
references.citation: Cancer Cell. 2005 Jul;8(1):61-74
references.pmid: 16023599
references.citation: Cancer Gene Ther. 2005 Aug;12(8):715-22
references.pmid: 15832172
references.citation: Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):861-8
references.pmid: 7591895
references.citation: Cancer Gene Ther. 2004 Feb;11(2):148-55
references.pmid: 14695756
references.citation: J Virol. 1998 Dec;72(12):9470-8
references.pmid: 9811680
references.citation: Crit Rev Oncol Hematol. 2001 Jun;38(3):177-92
references.pmid: 11369253
references.citation: Cancer Res. 2002 Sep 1;62(17):4968-76
references.pmid: 12208748
references.citation: Hum Gene Ther. 2003 Feb 10;14(3):227-41
references.pmid: 12639303
references.citation: Cancer Res. 2000 Mar 1;60(5):1193-6
references.pmid: 10728673
references.citation: Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1484-7
references.pmid: 12509912
references.citation: Hum Gene Ther. 1998 Jun 10;9(9):1323-33
references.pmid: 9650617
references.citation: J Biomed Biotechnol. 2003;2003(1):48-70
references.pmid: 12686722
references.citation: J Urol. 2000 Oct;164(4):1121-36
references.pmid: 10992352
references.citation: Cancer Res. 1997 Jul 1;57(13):2559-63
references.pmid: 9205053
references.citation: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references.pmid: 16514137
references.citation: Cancer Cell. 2004 Dec;6(6):611-23
references.pmid: 15607965
references.citation: Cancer Res. 2001 Jul 15;61(14):5453-60
references.pmid: 11454691
references.citation: Cancer Res. 2001 Aug 15;61(16):6012-9
references.pmid: 11507044
references.citation: J Clin Invest. 2000 May;105(9):1161-7
references.pmid: 10791987
references.citation: Cancer Res. 1994 Dec 1;54(23):6053-6
references.pmid: 7954444
references.citation: Mol Ther. 2000 Jan;1(1):56-62
references.pmid: 10933912
references.citation: Cancer Res. 1996 Oct 15;56(20):4614-9
references.pmid: 8840973
references.citation: Cancer Res. 2005 Mar 1;65(5):1941-51
references.pmid: 15753394
references.citation: Prostate. 2000 Oct 1;45(2):149-57
references.pmid: 11027414